Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Recent reports have emphasized the importance of the microenvironment in the development and pathophysiology of malignancies. Although most of these studies investigated interactions between stromal and neoplastic cells, hypoxia has emerged as another component of the microenvironment. Although hypoxia in solid tumors is well studied, it is unclear what role, if any, it has in the physiology of hematologic neoplasias. Lymphomas in this context may resemble solid tumors, but the hypoxic sanctuary for leukemias is thought to be the bone marrow. Hypoxia within the bone marrow of healthy individuals and cancer patients is of additional interest as it may affect hematopoietic progenitors and their differentiation 1 as well as bone metastases. Along with others, we have reported direct measurements of bone marrow pO 2 by a simple and minimally invasive method using conventional gas assay methodology routinely used clinically for the measurement of pO 2 .
2,3 Thus, the average bone marrow pO 2 ranged from 48.0 to 54.9 mm Hg. In our previous study, we found that simulation of this physiological hypoxia induces profound changes on the biology of acute myeloid leukemia (AML) cells, in particular expression and function of the chemokine receptor CXCR4, as well as changes in cell signaling, especially in the mitogen-activated protein kinase (MAPK) pathway. 3 This notion is of special interest as constitutive activation of the MAPK pathway has been linked to the development of AML 4 because of its critical function in proliferation, survival and differentiation, and its prognostic importance in AML. 5 We therefore aimed to analyze the relationship between physiological hypoxia and its influence on MAPK activation. In a first step, we examined potential differences in the levels of bone marrow hypoxia in patients with AML with active disease and in remission. Therefore, bone marrow aspirates were collected from AML patients who underwent routine bone marrow aspiration in heparinized syringes. The samples, comprising B2 ml of aspirate, were collected immediately after aspiration and analyzed within 5-10 min after aspiration for pO 2 Letters to the Editor by the Portable Clinical Analyzer (i-STAT corporation, Princeton, NJ, USA) with G3 þ cartridges (Abbott Inc., Princeton, NJ, USA). We compared the oxygen content of AML bone marrows (n ¼ 7) with that of patients in complete remission (CR, n ¼ 12). Although pO 2 in AML bone marrows tended to be lower (41.3±11.2 mm Hg) than in CR marrows (48.8±15.9 mm Hg), this difference was not significant and may in fact reflect anemia in AML patients (average Hb: 9.5±1.9 vs 12.0±2.1 g per 100 ml in the CR patients, Po0.01). One patient was available for analysis at diagnosis and at CR. At both time points, pO 2 of the bone marrow was 38.0 mm Hg, with an initial cellularity of 100% (50% blasts), decreasing to 30% (1% blasts, CR). Analysis according to high-risk (complex aberrant karyotype and/or fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT-3-ITD)) versus intermediate-risk groups (normal and intermediate karyotype) showed no significant difference between these groups (median 36.5 ± 14.2 vs 40.0 ± 3.5 mm Hg,
These data suggest that the infiltration of the bone marrow by leukemic blasts (as high as 80% in our patient group) does not have a significant affect on bone marrow oxygen levels. This can be explained by the anatomic-histological characteristics of the bone marrow cavity: this tissue consists, besides of fibrous stroma, of arterioles, venoles and, most importantly, of sinusoids, 6 making it an organ extremely well supplied with blood (and thus oxygen). It is important, however, to point out that these results do not rule out the existence of more hypoxic niches, which have been described in murine bone marrows, and are believed to be the sites in which hematopoietic stem cells home. 7 Our analysis reports the average O 2 content of ca. 2 ml of aspirated bone marrow, which may contain oxygen-rich and oxygen-low regions. Indirect measurements previously reported in animals may have a potential limitation in that before analysis the animals were killed, leading to decreased perfusion and thus widespread hypoxia, including the bone marrow. Therefore, the possibility of postmortem artifacts in areas with little or no perfusion/oxygen reserve (for example, areas distant from vessels) cannot be ruled out.
Next, we analyzed mechanisms involved in MAPK activation in AML at physiological hypoxia. To analyze the effect of physiological hypoxia on MAPK activation, we exposed AML cell lines and primary AML samples to 6% O 2 (pO 2 ¼ 45 mm Hg, as has been measured in the bone marrows). For these experiments in reduced oxygen environment, the hypoxic Workstation INVIVO 2 400 from Ruskinn Technology (Bridgend, UK) was used. In all, 6% O 2 induced a strong increase in the phosphorylation of Erk1/2 in AML cell lines Molm13, U937 ( Figure 1a ) and OCI-AML3 (average 4.4-fold increase in optical density (OD) on multiple blots (n ¼ 6)) after adjustment to 6% O 2 for at least 10 days as compared with their normoxic counterparts. In two primary samples from patients with AML, an average increase in OD in the pErk/Erk ratio of 1.7 was observed after 14-16 h of hypoxia (Figure 1b) . Viability was not different between the groups.
As the kinase for Erk1/2 is MEK1/2, we further analyzed the role of MEK1/2 in hypoxia-induced activation of MAPK 42/44. Both OCI-AML3 and Molm13 cells adjusted to 6% O 2 showed increased phosphorylation of MEK1/2 as compared with 21% O 2 (OCI-AML3 cells are shown in Figure 1c ). In addition, treatment with 100 nM PD98059 (a MEK1/2 inhibitor) for 1 h led to abrogation of Erk1/2 phosphorylation in both cell lines adjusted to physiological hypoxia (data not shown). Interestingly, both Erk1/2 and MEK1/2 were upregulated within the first hour of physiological hypoxia, and remained phosphorylated for the following 24 h. After 1 h at 6% O 2 , we did not observe an increase in hypoxia-inducible factor (HiF) 1a, implying no role for HiF 1a in this early activation process at this pO 2 .
We have recently shown that physiological hypoxia and re-oxygenation of cells exposed to hypoxia alters cellular membranes, notably lipid rafts, by increasing raft cholesterol content, GM1 ganglioside expression and lipid raft structure. 2 To test whether MAPK phosphorylation at 6% O 2 was dependent on lipid rafts, we used MbCD, an agent commonly used for the disruption of lipid rafts that removes cholesterol from the cellular membrane. Figure 1d shows the dosedependent decrease in the MEK1/2 and Erk1/2 phosphorylation at 6% O 2 but not at 21% O 2 . Instead, low doses of MbCD can increase Erk1/2 phosphorylation at normoxia indicating different raft functions at different levels of O 2 .
The canonical upstream-located regulator of the MEK/Erk signal cascade is Ras, which is located at the inner leaflet of the cellular membrane. We therefore hypothesized that physiological hypoxia increases MAPK activity by increasing Guanosine-5'-triphosphate (GTP)-bound Ras. Ras activation was assayed with a Ras activation assay (Cytoskeleton, Denver, CO, USA) and performed according to the manufacturer's protocol. In brief, active, GTP-bound Ras was pulled-down using the Rasbinding domain of Raf1 in the form a glutathione S-transferase fusion protein bound to colored gluthation beads. After immunoprecipitation, the beads were subjected to western blotting. Figure 2a shows indeed higher levels of GTP-bound Ras, that is, in its active form, at physiological hypoxia, both in Molm13 and OCI-AML3 cells. To further examine pathways involved in activation of MEK/Erk, we used the pan-Src-family inhibitor PP2. Interestingly, we did not observe an effect on MAPK phosphorylation at 6% O 2 and accordingly, phosphorylation of Ras activator Src was dramatically decreased at 6% O 2 (data not shown). These data imply that under physiological hypoxia Ras is either activated independently of Src or that Letters to the Editor activation of MAPK might be independent of increased Ras activation. We therefore tested the effect of MbCD on Ras activity. Although MbCD decreased MAPK phosphorylation (as shown above), it had no effect on Ras activity (Figure 2a) . These data indicate that Ras may be of minor importance for increased MAPK activity at 6% O 2 .
Recent reports have linked MAPK activation to lipid rafts 8 with one proposed mechanism being a phosphatidylinositol 3 kinase (PI3K)-dependent activation of MEK/Erk independent of Ras/Raf1. We therefore hypothesized that PI3K inhibition could inhibit Erk1/2 and MEK1/2 activation at physiological hypoxia but not at normoxia. To test this hypothesis, we analyzed the effect of PI3K inhibition with LY294002 on MEK/Erk and Akt activation at 6 and 21% O 2 . Figure 2b shows the effect of LY294002 on OCI-AML3 cells. Whereas exposure to 5 nM LY294002 for 1 h leads to a decrease in phosphorylation of Akt (at S473) at both 21 and 6% O 2 , it does not inhibit MAPK activation at 21% O 2 (but rather increases Erk1/2 phosphorylation in OCI-AML3 cells). At physiological hypoxia, however, both Erk1/2 and MEK1/2 activity is diminished by PI3K inhibition. Relative changes in OD of multiple experiments (n ¼ 3) were as follows: 5 nM LY249002 decreased Akt phosphorylation by 50% at normoxia and by 60% at physiological hypoxia; at 21% O 2 the average decrease on MEK1/2 phosphorylation was 10 and 40% increase for Erk1/2, whereas at physiologic hypoxia a 30% decrease was observed for both kinases. Taken together, these data show that physiological hypoxiainduced robust phosphorylation of Erk. Importantly, our data suggest that activation of the MEK/Erk signal cascade under physiological hypoxia is not controlled by canonical Ras/Raf1 signaling, but is promoted, at least in part, by PI3K (which also promotes Akt phosphorylation). The roleFor lack thereofFof Ras in this mechanism remains to be further elucidated. Although we found increased amounts of active Ras in physiological hypoxia, we did not find any consequences of MbCD on Ras activity in spite of the decreased MAPK activity. Altogether these data suggest that physiological hypoxia regulates MEK/Erk and Akt activation through lipid rafts independent from Ras/Raf1. Figure 2d summarizes our findings and suggests a possible mechanism for activation of the MEK/Erk pathway under Letters to the Editor physiological hypoxia. In this model, physiological hypoxia increases membrane cholesterol, which promotes lipid raft formation (as previously shown in Fiegl et al.
2
), which in turn leads to activation of PI3K, consequently activating both MEK/Erk and Akt. The connection between PI3K and lipid rafts has already been suggested 9 in normoxia and interactions between the PI3K pathway and the MEK/Erk signaling cascade are well established. In addition, the possibility that PI3K functions as an alternative activator of MEK/Erk under physiological conditions shortcutting Ras could also provide additional explanation as to why Ras inhibition, most notably by farnesyl transferase inhibitors, has not fulfilled its promise in clinical studies that their preclinical efficacy testing, performed in normoxia, suggested. Furthermore, inhibition of FLT-3-signaling in AML patients with FLT-3-ITD with Sorafenib did not result in consistent inhibition of pERK, as was expected. Figure 2c . Mice transplanted with cells adjusted to physiological hypoxia engrafted significantly faster (day 7: twofold (Po0.05), day 21: fourfold (Po0.01)) as measured by bioluminescence imaging using the IVIS200 Imaging System (Xenogen/Caliper Life Science, Hopkinton, MA, USA). This difference was lost 4 weeks after transplantation, and no difference in survival in the hypoxia-transplanted group as compared with controls was observed.
Certainly, this faster engraftment cannot be tied to increased MEK/Erk and Akt signaling alone, as we have previously shown that adjustment of cells to 6% O 2 also affects CXCR4 expression, a chemokine receptor responsible for trafficking of lymphocytes and homing of stem cells. Moreover, physiological hypoxia did not only alter CXCR4 expression but also the response to its natural ligand stromal cell-derived factor-1 (SDF-1). 2 These may affect homing and engraftment of leukemic cells reflected in initially increased tumor mass. Over time, previously normoxic cells will assume a hypoxic phenotype, this eliminating the initial growth and homing advantage of pre-injection hypoxic cells, or alternatively, hypoxic cells might lose their growth advantage over time.
In conclusion, our data show that physiological oxygen conditions in the bone marrow microenvironment activate the MEK/Erk signal cascade in the absence of activating mutations by a lipid raft-and PI3K-regulated mechanism, surprisingly independent of Ras/Raf1. Cells adjusted to hypoxia showed a more rapid engraftment in vivo. These observations stress the importance of studying AML cells under physiological conditions, in particular at physiological hypoxia and caution against translating signaling pathways established at unphysiological normoxic conditions, in fact 'hyperoxic' conditions, to physiologic tumor hypoxia.
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